Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Jemincare

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Orion Enters Into Exclusive Agreement with Jemincare for Novel Non-Opioid Drug Candidate for The Treatment of Pain

Details:

According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.

Lead Product(s): JMKX000623

Therapeutic Area: Neurology Product Name: JMKX000623

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Orion Pharma

Deal Size: Undisclosed Upfront Cash: $15.8 million

Deal Type: Agreement May 06, 2022

ASK
US

Upload
your Pipeline Activity

Green Valley Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Green Valley to Start US Trials of Algae-Based Alzheimer’s Drug

Details:

Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.

Lead Product(s): Sodium oligomannate

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY